Ikeda, K., Iwamoto, T., Furuta, S., Nakajima, H., Suzuki, K., Ida, T., . . . Ishikawa, J. (2023). Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. BMJ Publishing Group.
Chicago Style (17th ed.) CitationIkeda, Kei, et al. Efficacy and Safety of Dose Escalation of Tofacitinib in Refractory Anti-MDA5 Antibody-positive Dermatomyositis. BMJ Publishing Group, 2023.
MLA (9th ed.) CitationIkeda, Kei, et al. Efficacy and Safety of Dose Escalation of Tofacitinib in Refractory Anti-MDA5 Antibody-positive Dermatomyositis. BMJ Publishing Group, 2023.
Warning: These citations may not always be 100% accurate.